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Background: miR-663 is associated with many important biologic processes, such as the evolution, development,
viral infection, inflammatory response, and carcinogenesis among vertebrates. However, the molecular function and
mechanism of miR-663 in pancreatic cancer growth and invasion is still unclear.
Methods: Western blot and real-time PCR were used to study the expression level of eEF1A2 protein and miR-663
in pancreatic cancer tissues and cell lines. The Pearson χ2 test was used to determine the correlation between miR-663
expression and clinicopathologic features of patients. Patients’ survival was analyzed using the Kaplan–Meier method,
using the log-rank test for comparison. The biological function of miR-663 was examined by measuring cell
growth, cell invasion and apoptosis analysis in vitro and in vivo. miR-663 target gene and signaling pathway was
identified by luciferase activity assay and western blot.
Results: We found that, in pancreatic cancer, eEF1A2 was significantly upregulated but miR-663 was significantly
downregulated. Further results showed that the expression level of eEF1A2 and miR-663 was strongly associated
with TNM stage and node metastasis status of the patients. miR-663 and eEF1A2 were inversely correlated with each
other, and the changes in the expression levels of each can also predict the survival of patients with pancreatic cancer.
We identified miR-663 as a tumor attenuate molecular that attenuated the proliferation and invasion of pancreatic
cancer cells both in vitro and in vivo. Finally, we confirmed that the expression of eEF1A2 can partially restore the
pro-apoptotic and anti-invasion functions of miR-663.
Conclusions: miR-663 attenuated the proliferation and invasion of pancreatic cells both in vitro and in vivo by directly
targeting eEF1A2. miR-663 and eEF1A2 might be potential targets for the treatment of pancreatic cancer in the future.
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Pancreatic cancer is one of the poorest prognoses among
human tumors, with an overall 5-year survival rate of
less than 5% [1]. In spite of the continuous develop-
ments in clinical therapies and novel surgical techniques,
the survival of patients with pancreatic cancer has
remained poor for over 30 years [2]. Pancreatic cancer is
highly aggressive, wherein tissue invasion and remote
metastasis may occur during the early stages [3]. Be-
cause invasion and metastasis are the most formidable
obstacles preventing the effective treatment of pancreatic
cancer, it is therefore essential to explore the molecular* Correspondence: zhaogq@zzu.edu.cn
1College of Basic Medical Sciences, Zhengzhou University, Zhengzhou
450001, Henan Province, China
Full list of author information is available at the end of the article
© 2015 Zang et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.mechanisms that contribute to this aggressive behavior,
in order to improve the outcomes for patients.
miR-663, a member of the primate-specific miRNA
family, is associated with many important biologic pro-
cesses, including the evolution, development, viral infec-
tion, inflammatory responses, and carcinogenesis of
many vertebrate species [4-9]. However, its role in tumor
progression can be considered quite contradictory. Al-
though it acts as an oncogene that promotes the malig-
nancy of lung cancer, nasopharyngeal carcinoma, and
breast cancer [6,7], miR-663 may also act as a potential
tumor attenuate molecular in gastric cancer, colorectal
carcinoma, prostate cancer, and acute lymphoblastic
leukemia [8,9]. Overall speaking, the effect and mechan-
ism of miR-663 on pancreatic cancer remain unclear.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of the G protein family, and one of the four subunits
that constitute the eukaryotic elongation factor 1
[10,11]. And it has two identified isoforms, namely
eEF1A1 and eEF1A2. Unlike eEF1A1, which is expressed
almost ubiquitously, eEF1A2 is normally only present in
the heart, brain, and skeletal muscles [12-14]. eEF1A2 is
involved in a variety of biological processes such as cyto-
skeleton modification [13,14], targeting proteins for deg-
radation [15], heat shock response [16], apoptosis [17],
and phosphatidylinositol signaling [18,19]. eEF1A2 is
considered as an oncogene marker because it is highly
expressed in a subset of cancers, such as ovarian cancer
[20], breast cancer [21], and pancreatic cancer [22].
In the present study, we evaluated the expression and
clinical relevance of miR-663 and eEF1A2 in pancreatic
cancer. Additionally, we investigated the functional role
of miR-663 in the invasion of pancreatic cancer cell
lines. The contribution of miR-663 to pancreatic cancer
malignancy and the underlying molecular mechanisms
were also investigated. Our data demonstrate that miR-
663 has potential value as a prognostic marker and as a




Male 45 0.706 ± 0.1486
Female 23 0.750 ± 0.1272
Age (years)
<60 42 0.702 ± 0.1515
≥60 26 0.751 ± 0.1227
Diameter (cm)
<3 51 0.715 ± 0.1471
≥3 17 0.738 ± 0.1294
Location
Head 48 0.713 ± 0.1394
Body, tail 20 0.739 ± 0.1511
Differentiation
Well 13 0.643 ± 0.1667
Moderate 39 0.735 ± 0.1265
Poor 16 0.747 ± 0.1453
TNM stage
I-II 30 0.670 ± 0.1635
III-IV 38 0.760 ± 0.1098
Nodal status
Negative 36 0.688 ± 0.1632
Positive 32 0.757 ± 0.1057
*Indicated statistical significance (P < 0.05).Results
eEF1A2 is upregulated and miR-663 is downregulated in
pancreatic cancer
Western blot and real-time PCR were used to study the
expression level of eEF1A2 protein and miR-663 in pan-
creatic cancer tissues. To analyze the clinicopathological
significance of eEF1A2 and miR-663, we examined 68
primary pancreatic cancer tissues, as well as 68 normal
pancreas tissues, collected from sites adjacent to tumors.
The relationship between the expression level of eEF1A2
and miR-663, and the clinicopathologic characteristics in
pancreatic cancer patients were summarized in Table 1.
Compared with normal pancreatic tissues adjacent to tu-
mors, the expression level of eEF1A2 protein was generally
upregulated in pancreatic cancer tissues (Figure 1A, B). On
the contrary, the average expression level of miR-663 was
decreased in pancreatic cancer tissue (Figure 1C).
The further results showed that eEF1A2 and miR-663
expression level were strongly associated with the TNM
stage and nodal status of the patients, not associated
with age, gender, diameter, location and differentiation
(Table 1). We found that eEF1A2 expression was lower
in stage I-II, but higher in stages III-IV; this reflects thater patients
miR-663
P value Expression level P value
0.230 0.421 ± 0.2493 0.426
0.374 ± 0.1669
0.163 0.422 ± 0.2552 0.436
0.378 ± 0.1649
0.566 0.425 ± 0.2322 0.218
0.347 ± 0.1947
0.486 0.398 ± 0.2057 0.663
0.423 ± 0.2696
0.518 ± 0.3358
0.086 0.383 ± 0.1812 0.124
0.366 ± 0.1947
0.009* 0.498 ± 0.2742 0.004*
0.332 ± 0.1411
0.048* 0.464 ± 0.2623 0.017*
0.338 ± 0.1505
Figure 1 The expression levels of eEF1A2 protein and miR-663 in pancreatic cancer tissues and cell lines. A. The expression levels of
eEF1A2 protein in paired pancreatic cancer tissues and adjacent non-tumor tissues. B. eEF1A2 protein expression level in pancreatic cancer
tissues was higher than in adjacent non-cancerous tissues. C. miR-663 expression level in pancreatic cancer tissues was lower than in adjacent
non-cancerous tissues. D. eEF1A2 protein expression levels in TNM stage I-II were lower than in TNM stage III-IV in pancreatic cancer tissues.
E. eEF1A2 protein expression levels in pancreatic cancer tissues with positive node metastasis were higher than with negative node metastasis. F. miR-663
expression levels in TNM stageI-II were higher than in TNM stage III-IV in pancreatic cancer tissues. G. miR-663 expression levels in pancreatic
cancer tissues with positive node metastasis were lower than with negative node metastasis. H. eEF1A2 protein expression level in pancreatic
cancer cell lines were higher than in the normal pancreatic cell line. I. miR-663 expression level in pancreatic cancer cell lines were lower than
in the normal pancreatic cell line. J. eEF1A2 and miR-663 have an inverse correlation.
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(Figure 1D, Table 1). But the expression of miR-663 was
higher in stage I-II, whereas it is lower in stages III-IV,
this reflects that miR-663 has a significant correlation
with clinical stages (Figure 1F, Table 1). In addition, we
found that the level of eEF1A2 was higher in the pres-
ence of lymph node metastasis than in the absence of
lymph node metastasis (Figure 1E, Table 1). The expres-
sion level of eEF1A2 exhibits a different pattern from
miR-663 (Figure 1G, Table 1). The level of miR-663
was lower with lymph node metastasis than without
(Figure 1G, Table 1). Taken together, these data pro-
vided strong evidence that the miR-663 expression was
closely related to the progression and clinicopathologic
features of pancreatic cancer. We further tested the ex-
pression level of eEF1A2 and miR-663 in pancreaticcancer cell lines to analyze their clinicopathological
significance. Consistent with the result of the pancre-
atic cancer tissues, compared with the normal pancre-
atic cell line PDE6-C7, the expression level of eEF1A2
protein was generally upregulated in pancreatic cancer
cell lines (PANC-1, Capan-2, SW1990, BxPC3 and
AsPC-1) (Figure 1H). On the contrary, the basal ex-
pression level of miR-663 was generally downregulated
in pancreatic cancer cell lines (PANC-1, Capan-2,
SW1990, BxPC3 and AsPC-1) (Figure 1I). On the basis
of these results, we focused on miR-663 for further
functional studies on its roles in pancreatic cancer
pathogenesis.
To investigate the correlation between miR-663 and
eEF1A2, we examined their expressions in primary hu-
man pancreatic cancer tissues. Unlike the matched
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68 patients with pancreatic cancer, miR-663 was re-
duced, whereas eEF1A2 protein was increased, which
demonstrates a significant negative correlation (R2 = 0.624;
P < 0.01; Figure 1J). The data suggested that eEF1A2 and
miR-663 have an inverse correlation in pancreatic cancer
tissues.Figure 2 The survival of patient in pancreatic cancer. Patients’ survival
for comparison. A statistically significant difference (P < 0.05) was observed. A.
B. Differentiation was significantly associated with the survival of patients. C. T
D. Gender was not significantly associated with the survival of patients. E. Age
was not significantly associated with the survival of patients. G. Lymph n
patients. H. eEF1A2 expression was significantly associated with the survi
the survival of patients.eEF1A2 and miR-663 are associated with the survival of
patient in pancreatic cancer
We used Kaplan-Meier method to analyze the relationship
between clinicopathologic characteristics and patient sur-
vival rates, based on follow-up visits of pancreatic cancer pa-
tients. The results showed that tumor diameter (P < 0.001;
Figure 2A), differentiation (P < 0.001; Figure 2B), clinicalwas analyzed using the Kaplan–Meier method, with the log-rank test
Tumor diameter was strongly associated with the survival of patients.
he clinical stage was significantly associated with the survival of patients.
was not significantly associated with the survival of patients. F. Location
ode metastasis was significantly associated with the survival of
val of patients. I. miR-663 expression was significantly associated with
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(P < 0.001; Figure 2G) were all significantly associated
with the survival of patients. But the gender (P = 0.975;
Figure 2D), age (P = 0.523; Figure 2E) and location (P =
0.613; Figure 2F) were not significantly associated with
the survival of patients.
To validate the relationship between the expression of
eEF1A2 and miR-663, and the survival of patient in pan-
creatic cancer, we examined the endogenous eEF1A2
and miR-663 expression in pancreatic cancer tissues,
and we observed through the Kaplan-Meier analysis that
the patients with higher level of eEF1A2 (≥0.72) had
shorter survival (P < 0.001; Figure 2H). On the contrary,
the patients with higher level of miR-663 (≥0.397) had
longer survival (P < 0.001; Figure 2I). Taken together, the
results above suggest that eEF1A2 and miR-663 are both
associated with the survival of patient in pancreatic can-
cer. eEF1A2 and miR-663 may be potential biomarkers
for prognosis in patients with pancreatic cancer.
miR-663 attenuates pancreatic cancer cell proliferation
The frequent downregulation of miR-663 in both pan-
creatic cancer tissues and pancreatic cancer cell lines in-
dicated that miR-663 might play a role in pancreatic
cancer tumorigenesis. To explore the potential tumor at-
tenuate effect of miR-663, we first synthesized a miR-
663 agomir or a miR-663 scramble, and then transfected
PANC-1 and AsPC-1 cells with them. The upregulated
expression of miR-663 was confirmed by Real-time PCR
(Figure 3A). CCK-8 and colony formation assays were
utilized to evaluate cell proliferative capacity. As was
shown in Figure 3B and C, after transfection for 24 h,
48 h and 72 h, the miR-663 group revealed a significant
slower proliferation than the control groups (Blank and
NC groups) for PANC-1 (Figure 3B) and AsPC-1 cells
(Figure 3C). Consistent with the results of CCK8, The
upregulated expression of miR-663 also visibly attenu-
ated colony formation. The colony numbers of PANC-1
(Figure 3D) and AsPC-1 cells (Figure 3E) were 62.3 ± 8.4
and 42.5 ± 5.7, respectively, in miR-663 group. These re-
sults suggested that miR-663 could attenuate the prolif-
eration of pancreatic cancer cells in vitro, and might
function as tumor attenuate molecular in vitro.
miR-663 attenuates pancreatic cancer cell invasiveness
We next tested whether miR-663 could alter the inva-
siveness of pancreatic cancer cells in vitro. To study the
effect of miR-663 on the invasiveness of pancreatic can-
cer, PANC-1 and AsPC-1 cells were transfected with ei-
ther miR-663 agomir (miR-663 group) or miR-663
scramble using a Matrigel model (NC group). In vitro,
more specifically in the PANC-1 (18.4 ± 3.2, P < 0.01,
Figure 4A) and AsPC-1 (15.7 ± 3.1, P < 0.01, Figure 4B)
cells, pancreatic cancer’s invasive growth was significantlyimpaired when transfected with miR-663 agomir, as com-
pared to the Blank and NC groups.
The matrix metalloproteinases (MMPs) are family
members of extracellular proteinases that regulate basic
cellular processes including survival, migration, morpho-
genesis and degradation of extracellular matrix during
the cancer metastatic process [23,24]. Among the MMPs
members, MMP9 cleaves the extracellular domain of
NOTCH1 and activates NOTCH1 downstream target
gene expression [25,26]. Akt, also known as protein kin-
ase B (PKB), is a serine/threonine-specific protein kinase
that plays a key role in multiple cellular processes such
as glucose metabolism, apoptosis, cell proliferation, tran-
scription and cell migration [27]. Once correctly posi-
tioned at the membrane via PIP3 binding, Akt can then
be phosphorylated by its activating kinases. Akt regulates
cellular survival and metabolism by binding and regulat-
ing many downstream effectors [28]. We examined the
expression levels of MMP9, Akt and pAkt(Ser473), and
found that the ectopic expression of miR-663 markedly
attenuated the protein expression of MMP9, Akt and
pAkt in both PANC-1 (Figure 4C) and AsPC-1 cells
(Figure 4D), and is concomitant with the attenuation of
cell invasion. These results suggest that miR-663 could
attenuate pancreatic cancer cell invasiveness, which is
likely associated with MMP9 and Akt.
miR-663 induces cell apoptosis
To determine whether the decrease in pancreatic cancer
growth by miR-663 was due to an induction of apop-
tosis, we evaluated the rate of cellular apoptosis using
the FITC Annexin V Apoptosis Detection Kit I (BestBio,
Shanghai, China) by flow cytometry. The results showed
that the numbers of both early and late apoptotic cells at
48–96 h post-transfection of miR-663 agomir in PANC-
1 (Figure 5A) and AsPC-1 cells (Figure 5B) significantly
increased when compared to the miRNA transfected
control group (NC group). Consistent with the results
from the flow cytometry assay, the upregulated expres-
sion of miR-663 also noticeably induced apoptosis of
PANC-1 (Figure 5C) and AsPC-1 cells (Figure 5D) in
the Hoechst 33342 staining assay. The results suggest
that miR-663 induces cell apoptosis.
BAD, a protein related to Bcl-2, is a promoter of apop-
tosis, which has been shown to dimerize with anti-
apoptotic proteins Bcl-2 and Bcl-XL. BAD connects the
upstream signal transduction paths with the BCL-2 fam-
ily, and modulate this checkpoint for apoptosis [29].
BAX, a death-promoting member critical to cell death,
heterodimerizes with multiple death-repressing mole-
cules [30]. Induction of apoptosis was further confirmed
by the expression of apoptosis related proteins using
western blot. As shown in Figure 5E and F, the protein
levels of BAD, BAX, and cleaved caspase-3 were
Figure 3 miR-663 attenuates pancreatic cancer cell proliferation. A. The expression of miR-663 was upregulated in the cells trasfected with
miR-633 agomir. The expression of miR-663 was measured by RT-PCR. B. A statistically significant decrease in PANC-1 cell proliferation in the miR-
663 group was observed compared to the Blank and NC groups. Effect of miR-663 on cell proliferation was measured by CCK-8 assay. C. A statistically
significant decrease in AsPC-1 cell proliferation in the miR-663 group was observed compared to the Blank and NC groups. Effect of miR-663 on cell
proliferation was measured by CCK-8 assay. D. miR-663 transfection of PANC-1 reduced growth of colonies. Colony formation in soft agar after 14 days
using PANC-1 exposed to miR-663. Quantification of clone number per 10× microscopic field for cells exposed to miR-663 in duplicate experiments
performed with triplicate wells. Compared to the Blank and NC groups, a significant reduction (*P< 0.05) in colony forming potential was observed after
treatment with miR-663 as assessed by counting the number of clones. E. miR-663 transfection of AsPC-1 reduced growth of colonies. Colony
formation in soft agar after 14 days using AsPC-1 exposed to miR-663. Quantification of clone number per 10× microscopic field for cells
exposed to miR-663 in duplicate experiments performed with triplicate wells. Compared to the Blank and NC groups, a significant reduction
(*P < 0.05) in colony forming potential was observed after treatment with miR-663 as assessed by counting the number of clones.
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cells compared to the Blank and NC groups. These re-
sults inferred that miR-663 induced cell apoptosis by
regulating the BAD-dependent apoptosis pathway. The
apoptosis must be contributing factors leading to the
growth attenuation in pancreatic cancer cells that ex-
press miR-663.
miR-663 attenuates tumor growth in vivo
To further confirm the growth-attenuating effect of
miR-663 on pancreatic cancer, a xenograft tumor growth
assay was performed. The subcutaneous tumor volumegrowth curve of PANC-1 stably expressed miR-663 or
Blank control in vivo was shown in Figure 6A. The
tumor volume was significantly lower in the miR-663
nude mice as compared to the control mice at 2, 3,
4 week. (P < 0.05, Figure 6A). After 4 weeks, the tumors
were harvested (Figure 6B). The total weight of the
metastatic tumors was significantly lower in miR-663
nude mice as compared to the control mice (Figure 6C).
Our results revealed that miR-663 could attenuate the
proliferation of pancreatic cancer cells in vivo. These re-
sults provide further evidence that miR-663 plays a
tumor attenuated role in pancreatic cancer.
Figure 4 miR-663 attenuates pancreatic cancer cell invasiveness. A. miR-663 attenuates pancreatic cancer PANC-1 cell invasiveness. Invasive
ability of PANC-1 after transfection was assessed using Transwell assays. The number of invasive miR-663-transfected PANC-1 cells was significantly
lower than in the Blank and NC groups. *P < 0.05 compared to the control group. B. miR-663 attenuates pancreatic cancer AsPC-1 cell invasiveness.
Invasive ability of AsPC-1 after transfection was assessed using transwell assays. The number of invasive miR-663-transfected AsPC-1cells was significantly
lower than in the Blank and NC groups. *P < 0.05 compared to the control group. C. miR-663 attenuates protein expression of MMP9, Akt, pAkt and
eEF1A2 in PANC-1 cells. Protein expression was measured by Western blot assay. miR-663 significantly attenuates protein expression of MMP9 , Akt and
pAkt in PANC-1 cells compared to the Blank and NC groups. β-actin was used as a reference. D. miR-663 attenuates protein expression of MMP9, Akt,
pAkt and eEF1A2 in AsPC-1 cells. Protein expression was measured by Western blot assay. miR-663 significantly attenuates protein expression of MMP9,
Akt and pAkt in AsPC-1 cells compared to the Blank and NC groups. β-actin was used as a reference.
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We searched for the direct target of miR-663 based on
the following criteria: the target should have oncogenic
property and should regulate cell migration and inva-
sion. Among these targets of miR-663 predicted by the
bioinformatics algorithms (TargetScan and miRBase), we
focused on eEF1A2. The 3′ untranslated region (3′UTR)
of eEF1A2 contains a seed region for miR-663 (Figure 7A).
To test the specific regulation through the seed region, we
constructed a reporter vector which consists of the lucifer-
ase coding sequence followed by the 3′UTR of eEF1A2.
Either the wild type (pmirGLO-eEF1A2-3′UTR) or the
mutated sequence (pmirGLO-eEF1A2-mut 3′UTR) within
the seed region sites was cloned into the pmirGLO re-
porter vector (Figure 7A). Co-transfection experi-
ments showed that miR-663 significantly decreased the
luciferase activity of the wild type in PANC-1 (P < 0.05,
Figure 7C) and AsPC-1 cells (P < 0.05, Figure 7D); but this
was not observed in the mutant type (Figure 7C, D). Our
data thus demonstrated that eEF1A2 was a direct target of
miR-663.
To further confirm that miR-663 targets eEF1A2, miR-
663 agomir or miR-663 scramble was transfected into
PANC-1 and AsPC-1 cells. Transfection of miR-663 ago-
mir resulted in significant reduction of eEF1A2 protein
expression by western blot in PANC-1 and AsPC-1 cells,
respectively (P < 0.05, Figure 7B). These results showthat miR-663 targets eEF1A2 by binding to its 3′UTR in
pancreatic cancer cells.
Expression of eEF1A2 could partially restore the
pro-apoptotic function and anti- invasion of miR-663
To explore the function of eEF1A2 in pancreatic cancer
cells, we constructed pcDNA3.1- eEF1A2 lacking the 3′
UTR, and we then transfected them into PANC-1 cells.
Western blot assay showed that the transfection of
miR-663 agomir inhibited the expression of eEF1A2
(Figure 8A). Co-transfection of pcDNA3.1-eEF1A2 and
miR-663 abrogated the effects of miR-663 on eEF1A2
expression (Figure 8A). Our apoptosis assay indicated
that the exogenous expression of miR-663 increased
cell apoptosis that was induced by serum starvation
(Figure 8B). Subsequently, we exogenously expressed
the recombinant eEF1A2 lacking the 3′ UTR sequence
(pcDNA3.1-eEF1A2) in PANC-1 cells. Cells transfected
with pcDNA3.1-eEF1A2 alone showed significantly de-
creased levels of apoptosis (Figure 8B). However, when
we co-transfected the cells with pcDNA3.1-eEF1A2 and
miR-663, the expression of eEF1A2 lacking the 3′ UTR
sequence was found to restore the pro-apoptotic func-
tions of miR-663 (Figure 8B).
In the transwell assays we found that the exogenous
expression of miR-663 decreased cell invasiveness
(Figure 8C). Subsequently, we exogenously expressed
Figure 5 miR-663 induces cell apoptosis in PANC-1 and AsPC-1 cells. A. miR-663 induces PANC-1cell apoptosis. The apoptosis cells of PANC-1 were
assessed using flow cytometry assay. The number of apoptosis miR-663-transfected PANC-1 cells was significantly higher than in the Blank and NC groups.
*P < 0.05 compared to the control group. B. miR-663 induces AsPC-1 cell apoptosis. The apoptosis cells of AsPC-1 were assessed using flow cytometry
assay. The number of apoptosis miR-663-transfected AsPC-1 cells was significantly higher than in the Blank and NC groups. *P < 0.05 compared to the
control group. C. Results from Hoechst 33342 staining assay showed that transfection with the miR-663 agomir led to a significant increase in PANC-1 cell
apoptosis compared to the Blank and NC groups (P< 0.05). D. Results from Hoechst 33342 staining assay showed that transfection with the miR-663
agomir led to a significant increase in AsPC-1 cell apoptosis compared to the Blank and NC groups (P< 0.05). E. miR-663 increased protein expression of
BAD, BAX, and cleaved caspase-3 in PANC-1 cells. Protein expression was measured by Western blot assay. The protein levels of BAD, BAX and cleaved
caspase-3 were enhanced in miR-663 group in PANC-1 cells compared to the Blank and NC groups. β-actin was used as a reference. F. miR-663 increased
protein expression of BAD, BAX and cleaved caspase-3 in AsPC-1 cells. Protein expression was measured by Western blot assay. The protein levels of BAD,
BAX and cleaved caspase-3 were enhanced in miR-663 group in AsPC-1 cells compared to the Blank and NC groups. β-actin was used as a reference.
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(pcDNA3.1- eEF1A2) in PANC-1 cells. Cells trans-
fected with pcDNA3.1- eEF1A2 alone showed signifi-
cantly increased cell invasiveness (Figure 8C). But
when the cells were co-transfected with pcDNA3.1-
eEF1A2 and miR-663, the expression of eEF1A2 lack-
ing the 3′ UTR sequence was found to restore the
anti-invasion of miR-663 (Figure 8C). From these re-
sults we concluded that the expression of eEF1A2
could partially restore the pro-apoptotic function and
anti-invasion of miR-663.eEF1A2 silencing and miR-663 overexpression exert
anti-proliferative, anti-invasive and pro-apoptotic effects
on pancreatic cancer cells
To further explore the biological significance of eEF1A2
and miR-663 in pancreatic cancer cells, eEF1A2-siRNAs
and miR-663 agomir were transfected into PANC-1 cells.
CCK8 array showed that the silencing of eEF1A2 and
the overexpression of miR-663 attenuated cell prolifera-
tion (Figure 9A). This attenuation is more obvious in
PANC-1 cells overexpressing miR-663. Furthermore,
Colony formation assay obtained the same results—
Figure 6 MiR-663 inhibited tumor growth in vivo. A. The subcutaneous tumor volume growth curve of PANC-1 stably expressed miR-663 or
Blank control in vivo was shown. The tumor volume was significantly lower in miR-663 nude mice as compared to the control nude mice. B. Tumors
were harvested after 4 weeks. C. The total weight of the metastatic tumors in each group. Significant difference (*P < 0.05).
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pression of miR-663 attenuated PANC-1 cells prolifera-
tion (Figure 9B). Invasion assay showed that the
knockdown of eEF1A2 and the overexpression of miR-
663 repressed the invasion and invasion capacities of
PANC-1 cells (Figure 9C). For PANC-1 cells over-
expressing miR-663, the invasion was more clearly attenu-
ated (Figure 9C). To investigate the effect of eEF1A2-siRNAs
and miR-663 on apoptosis, we performed apoptosis
assay. As showed in Figure 9D, compared to the BlankFigure 7 eEF1A2 is the direct target of miR-663 in PANC-1 and AsPC-
UTRs. The 3′ untranslated region (3′UTR) of eEF1A2 contains a seed region
cells. Transfection of miR-663 agomir resulted in significant reduction of eE
β-actin was used as a reference. C. miR-663 significantly decreased the lucifera
luciferase activity of wild type in AsPC-1 cells. (*P < 0.05).control, eEF1A2 silencing and the overexpression of
miR-663 significantly induced PANC-1 cell apoptosis.
To further determine the mechanisms underlying pan-
creatic cancer attenuation by miR-663, we focused our
investigation on whether BAD, BAX, cleaved caspase-3,
MMP9 and AKT were associated with the miR-663-
induced attenuated proliferation, invasion and pro-
apoptotic. As shown in Figure 9E, together with their
protein abundances, MMP9, pAKT and eEF1A2 were
significantly reduced in the PANC-1 cells overexpressing1 cells. A. The putative miR-663 binding sequences for the eEF1A2 3′
for miR-663. B. Western blot analysed eEF1A2 expression in transfected
F1A2 protein expression by western blot in PANC-1 and AsPC-1 cells.
se activity of wild type in PANC-1. D. miR-663 significantly decreased the
Figure 9 eEF1A2 silencing and miR-663 overexpression exert anti-proliferative, anti-invasive and pro-apoptotic effects on pancreatic
cancer cells. A. eEF1A2 silencing and miR-663 overexpression inhibited the proliferation. CCK8 array was used to assess PANC-1 proliferation.
B. eEF1A2 silencing and miR-663 overexpression reduced growth of colonies of PANC-1 cells (*P < 0.05). Colony formation assay was used.
C. eEF1A2 silencing and miR-663 overexpression suppressed PANC-1 cell invasiveness. Invasive ability of PANC-1 after transfection was assessed
using Transwell assays. (*P < 0.05). D. eEF1A2 silencing and miR-663 overexpression induced PANC-1cell apoptosis. The apoptosis cells of PANC-1
were assessed using flow cytometry assay. (*P < 0.05). E. Protein level was detected by western blot assay. MMP9, pAKT and eEF1A2 were significantly
reduced, and that BAD, BAX and cleaved caspase-3 were significantly increased in the miR-663 overexpressing and eEF1A2 silencing cells. β-actin was
used as a reference.
Figure 8 Expression of eEF1A2 restored the pro-apoptotic function and anti-migration of miR-663. A. eEF1A2 protein level was detected
by western blot assay. Cells were transfected with pcDNA3.1- eEF1A2 (not including 3′UTR) or (and) miR-663. Western blot assay showed that
transfection of miR-663 agomir inhibited the expression of eEF1A2. Co-transfection of pcDNA3.1- eEF1A2 and miR-663 abrogated the effects of
miR-663 on eEF1A2 expression. β-actin was used as a reference. B. Expression of eEF1A2 restored the pro-apoptotic function of miR-663. Cells
were transfected with pcDNA3.1- eEF1A2 (not including 3′ UTR) or (and) miR-663. The cell apoptosis were assessed using flow cytometry assay.
Co-transfected cells with pcDNA3.1- eEF1A2 and miR-663, the expression of eEF1A2 lacking the 3′ UTR sequence was found to restore the
pro-apoptotic functions of miR-663. C. Expression of eEF1A2 restored the anti-migration function of miR-663. Cells were transfected with pcDNA3.1-
eEF1A2 (not including 3′ UTR) or (and) miR-663. Invasive ability was assessed using transwell assays. Co-transfected cells with pcDNA3.1- eEF1A2 and
miR-663, the expression of eEF1A2 lacking the 3′ UTR sequence was found to restore the anti-migration functions of miR-663.
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as compared to control ones. BAD, BAX and cleaved
caspase-3 were significantly increased in the PANC-1
cells overexpressing miR-663 and PANC-1 cells with si-
lenced eEF1A2. According to these results, we found
that the knockdown of eEF1A2 and the overexpression
of miR-663 result in similar biological effect on pancre-
atic cancer cells, and that the attenuation is more evi-
dent in PANC-1 cells overexpressing miR-663. The
result revealed that the attenuation effect of miR-663 on
pancreatic cancer occurs at least partially by targeting
eEF1A2; at the same time, there were other targets tak-
ing part in the process. The study demonstrated that
miR-663 can act as a potential target for the treatment
of pancreatic cancer in the future.Discussion
miR-663 is expressed in Homo sapiens and Pan troglo-
dytes. miR-663 belongs to the primate-specific miRNAs
that possibly attribute to the vertebrates’ evolution, de-
velopment, and carcinogenesis [31-34]. The effect of
miR-663 in malignant progression is controversial, be-
cause it could act as a tumor attenuate molecular or
promoter in an organ-specific fashion [6,7]. The clinical
relevance of miR-663 in pancreatic cancer remains un-
known. Our present study represents the first compre-
hensive analysis of miR-663 in pancreatic cancer. We
selected miR-663 as the target molecule from miRNA
profiling, and then identified miR-663 as a tumor at-
tenuate molecular that can attenuate the proliferation
and invasion of pancreatic cancer. Mechanistically, we
identified eEF1A2 as a direct and functional target of
miR-663, which deepened our understanding of the
mechanisms underlying pancreatic cancer progression.
Our study has demonstrated that eEF1A2 is signifi-
cantly upregulated and miR-663 is significantly downreg-
ulated in pancreatic cancer. The additional results
showed that eEF1A2 and miR-663 expression level were
significantly associated with TNM stage and node metas-
tasis status of the patients, but not associated with the
patient’s age or gender, or with the tumor’s diameter, lo-
cation or differentiation. Furthermore, while the tumor’s
diameter, differentiation, clinical stage and lymph node
metastasis were significantly associated with the survival
of patients, the gender, age, and location were not. Since
eEF1A2 and miR-663 are both associated with the sur-
vival of patient in pancreatic cancer, both may be poten-
tial biomarkers for prognosis in patients with pancreatic
cancer.
Most importantly, we found that miR-663 and eEF1A2
were not only correlated inversely with each other, but
were also predictive of the survival of pancreatic cancer
patients. These findings highlight the potential values ofmiR-663 and eEF1A2 as novel prognostic biomarkers in
human pancreatic cancer.
Pancreatic cancer is characterized by rapid growth
and relentless invasion. Invasiveness and metastasis,
the two leading causes of cancer mortalities, are espe-
cially pronounced in pancreatic cancer, which shows
strikingly high invasive and metastatic potential [3]. We
highlighted the therapeutic potential of miR-663 in
pancreatic cancer treatment with our identification of
miR-663 as a tumor attenuate molecular that attenuates
the proliferation and invasion of pancreatic cancer cells
both in vitro and in vivo, and that attenuates of growth
and invasion of pancreatic cancer. MMPs regulate basic
cellular processes including survival, migration and
morphogenesis and degradation extracellular matrix
during the cancer metastatic process [23]. Akt plays a
key role in multiple cellular processes such as glucose
metabolism, apoptosis, cell proliferation, transcription
and cell migration [27]. We examined the expression
levels of MMP9, Akt and pAkt(Ser473), and then found
that the ectopic expression of miR-663 markedly atten-
uated the protein expression of MMP9, Akt and pAkt,
in PANC-1 and AsPC-1 cells concomitant with the at-
tenuation of cell invasion. These results suggest that
miR-663 attenuates pancreatic cancer cell invasiveness,
a property likely associated with MMP9 and Akt.
Eukaryotic elongation factor 1 alpha (eEF1A) is critical
for protein synthesis because it regulates ribosomal poly-
peptide elongation by binding to amino-acylated tRNAs
and by facilitating recruitment to the ribosome [35]. The
two isoforms of eEF1A identified in humans, namely,
eEF1A1 and eEF1A2, are encoded by distinct genes.
eEF1A2 is a protein translation factor with important
functions in tumor genesis and progression, for it is fre-
quently overexpressed in various cancers. One recent
study had demonstrated that eEF1A2 promoted cell
invasion in pancreatic cancer by upregulating the
expression of MMP-9 through Akt activation [22]. We
identified eEF1A2 as a direct target of miR-663 by
bioinformatics prediction, signal network analysis
and Dual-luciferase assay. The 3′ untranslated region
(3′UTR) of eEF1A2 contains a seed region for miR-663.
Our pancreatic cancer tissue study has showed that
eEF1A2 was significantly upregulated and miR-663 was
significantly downregulated in pancreatic cancer. Most
importantly, we found that miR-663 and eEF1A2 were
inversely correlated with each other. These results fur-
ther supported the conclusion that miR-663 targets
eEF1A2.
Additionally, further study indicated that the expres-
sion of eEF1A2 could partially restore the pro-apoptotic
and anti-invasion functions of miR-663. The knockdown
of eEF1A2 and the overexpression of miR-663 produce
similar biological effects on pancreatic cancer cells, with
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pressing miR-663. The results revealed that the attenu-
ation effect of miR-663 on pancreatic cancer was due at
least in part to its targeting of eEF1A2, at the same time
there were other targets taking part in the process. Our
study has demonstrated the potential of miR-663 as a
target for future pancreatic cancer treatments.
In summary, the study revealed that eEF1A2 was sig-
nificantly upregulated and miR-663 was significantly
downregulated in pancreatic cancer, and that both
EEF1A2 and miR-663 are associated with the survival of
pancreatic cancer patients. Moreover, miR-663 and
eEF1A2 were correlated inversely with each other. Spe-
cifically, miR-663 attenuated the proliferation and inva-
sion of pancreatic cells in vitro and in vivo by directly
targeting eEF1A2. Most importantly, miR-663 and
eEF1A2 may prove to be novel prognostic biomarkers
and potential targets for future treatments of pancreatic
cancer.
Conclusions
In conclusion, we have identified that miR-663 attenu-
ated the proliferation and invasion of pancreatic cells
in vitro and in vivo by directly targeting eEF1A2. miR-
663 and eEF1A2 might be potential targets for the treat-
ment of pancreatic cancer in the future.
Materials and methods
Patients and tissue specimens
The tissue specimens were collected from 68 patients with
pancreatic cancer who had undergone either pancreatico-
duodenectomy or distal pancreatectomy between 2007
and 2009 at the First Affiliated Hospital of Zhengzhou
University and the Henan Tumor Hospital of Zhengzhou
University in Zhengzhou, China.
After the frozen specimens were HE stained and ex-
amined for clinicopathological features by surgical pa-
thologists, they were then snap frozen in liquid nitrogen.
Normal pancreas tissues adjacent to tumors were used
as controls. None of the cancer patients in this study
had received preoperative radiation or chemotherapy.
Informed consent was obtained from the patients. The
clinicopathologic features of these patients have been
summarized in Table 1. The 68 patients with complete
information were followed up after operation until
February 1st, 2014, with a median follow-up time of
17.8 months. The study was approved by the Research
Ethics Committee of Zhengzhou University.
Cell culture
Human pancreatic cell line HPDE6-C7 and pancreatic
cancer cell lines PANC-1, Capan-2, SW1990, BxPC3 and
AsPC-1 were purchased from the Type Culture Collection
of the Chinese Academy of Sciences (Shanghai, China).Subsequently, these cell lines were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS,
Gibco, Australia), 100 U/ml penicillin, and 50 μg/ml
streptomycin in incubators with humidified atmosphere of
5% CO2 and 95% air at 37°C.
miRNA transfection
The miR-663 agomir (GMR-miR™ microRNA-663 ago-
mir) used in this study was synthesized by Shanghai
GenePharma Co. Ltd. Prior to transfection, cells were
plated at a density of 1.5 × 105 cells/well in 6-well
plates. Once cells reached ~70% confluence, transient
transfection was conducted using Lipofectamine™2000
(Invitrogen, Carlsbad, CA, USA) following the manu-
facturer’s instructions. Transfection efficiencies were
evaluated in every experiment by qRT-PCR at 24 h
post-transfection. Cells from each cell line were subdi-
vided into three groups: the non-transfected blank
group (Blank), the scrambled miR-663 transfected
negative control group (NC) and the miR-663 agomir
transfected group (miR-663).
Quantitative real-time PCR
Total RNA wasextracted frompancreatic cancer tissue
samples and adjacent non-tumor tissue samples using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s instructions. 1 μg RNA was
used to synthesize cDNA. And the expression levels of
eEF1A2 and miR-663 were determined by qPCR (ABI
7500 fast system, Applied Biosystems, CA, USA). We
used U6 small nuclear RNA (U6 snRNA) as an endogen-
ous control for normalization. The qRT-PCR results
were expressed relative to miR-663 expression levels at
the threshold cycle (Ct) and were converted to fold
changes (2-ΔΔCt).
Western blot analysis
Total proteins of cells were extracted using RIPA buffer
containing phenylme thanesulfonylfluoride (PMSF). The
protein obtained was measured using a BCA Protein
Assay Kit (Pierce, Rockford, IL). 30 μg of protein lysates
were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto
PVDF membranes. PVDF membranes were blocked in
5% BSA in 0.05% tween 20-TBS for 1 h and incubated
with primary antibody overnight at 4 diluted in forego-
ing blocking buffer. Dilutions for primary antibodies
were as follows: anti-eEF1A2 (1:1000, Santa Cruz, USA),
anti-MMP-9 (1:400, Santa Cruz, USA), anti-total Akt
(1:1000, Santa Cruz, USA), anti-p-Akt (Ser 473) (1:1000,
Santa Cruz, USA), anti-BAD(1:1000, Santa Cruz, USA)
anti-BAX (1:1000, Santa Cruz, USA). After extensive
washing with TBST, anti-rabbit IgG-HRP secondary anti-
body (1:5000, Santa Cruz, USA) was added. Signals were
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(Amersham Pharmacia Biotech, Piscataway, NJ). An
antibody against β-actin (Santa Cruz, USA) served as an
endogenous reference.
Cell proliferation assay
The pancreatic cancer cells were transferred to 96-wells
plates at a density of 1 × 104 cells/well, with five replicate
wells per group. Then the relative numbers of viable
cells were detected by Cell Counting Kit-8 reagents
(CCK-8; Dojindo, Japan) after 0, 1, 2, 3 days of cultiva-
tion. The results were recorded using a microplate
reader (Elx800; BioTek, VT, USA), in absorbance optical
density at 450 nm. The experiments were independently
triplicated.
Colony formation assay
Human pancreatic cancer cell linesPANC-1 and AsPC-1
were seeded and transfected with miR-663. Cells were
suspended in RPMI-1640 containing 0.35% low melting
agarose, and plated onto solidified 0.6% agarose contain-
ing RPMI-1640 in six-well culture plates at a density of
1 × 105 cells per dish. The plates were incubated for
2 weeks at 37 in a 5% CO2 incubator, and the number of
colonies was counted after staining with 0.1% crystal vio-
let solution. The colonies of more than 50 cells were
manually counted. The experiments were independently
triplicated.
Transwell assay
Transwell filters (Costar, USA) were coated with matri-
gel (3.9 μg/μl, 60–80 μl) on the upper surface of the
polycarbonic membrane (6.5 mm in diameter, 8 μm pore
size). After 30 min of incubation at 37°C, the matrigel
solidified and served as the extracellular matrix for
tumor cell invasion analysis. Cells of the transfected and
control groups (1 × 105) were harvested in 100 μl of
serum free RPMI-1640 medium and added to the upper
compartment of the chamber. After 24 h of incubation
at 37°C and 5% CO2, the medium was removed from the
upper chamber, and then stained with methylene blue
Staining Solution (Beyotime). Noninvasive cells on the
upper surface were wiped with a cotton swab. The num-
ber of cells invading the matrigel was counted from
three randomly selected visual fields, each from the cen-
tral and peripheral portion of the filter, using an inverted
microscope at 200× magnification. All experiments were
performed in triplicate.
Flow cytometry assay
Cell apoptosis was performed by flow cytometry. Human
pancreatic cancer cell lines PANC-1 and AsPC-1 cells
were harvested at 48 h post-transfection by trypsiniza-
tion. Tumor cells were resuspended at a density of 1 ×106 cells/mL in 1 × binding buffer. After double staining
with FITC-Annexin V and propidium iodide (PI) using
the FITC Annexin V Apoptosis Detection Kit I (BestBio,
Shanghai, China), cells were analyzed using a FACScan®
flow cytometer equipped with Cell Quest software (BD
Biosciences, San Jose, CA, USA) according to manufac-
turer’s instructions to detect early and late apoptosis of
cells. All experiments were performed in triplicate.
Hoechst 33342 staining
Cells were treated with different concentrations of
a1-PDX for 48 h and washed twice with cold PBS, and then
incubated in the dark in 5 μL Hoechst /PI staining buffer
for 15 min at 25°C. The images were recorded on a com-
puter with a digital camera attached to the microscope,
and then images were processed by the computer. The
Hoechst reagent was taken up by the nuclei of the cells,
and apoptotic cells exhibited a bright blue fluorescence.
For quantification of Hoechst 33342 staining, the percent-
age of Hoechst-positive nuclei per optical field (at least 50
fields) was counted. All experiments were performed in
triplicate.
Tumor xenograft model of nude mouse
Six-week-old male nude BALB/c mice were purchased
from Henan Experimental Animals Centre (Zhengzhou,
China). Tumor xenograft model of nude mouse is a reli-
able in vivo model for tumor study. To assess the effect
of miR-663 on tumorigenicity in vivo, we purchased
lentivirus expressing pre-miR-663 from Shanghai Gene
Pharma Co. Ltd and infected it into the PANC-1 cells.
The 2 × 106 stably transfected cells are subcutaneously
injected in the dorsal scapular region of 6-week-old
BALB/c nude mice (6 mice/group), which had been
anesthetized by inhaling sevoflurane. The tumors formed
were measured with a caliper every 7 days, and tumor
volume was calculated using the following formula: vol-
ume =Л (length × width2)/6. Tumors were harvested
after 4 weeks. These protocols were approved by the
Zhengzhou University Animal Care and Use Committee.
Dual-luciferase assay
Human eEF1A2 3′ UTR (bases108-115) fragment con-
taining putative binding sites for miR-663 were amplified
by PCR from human genomic DNA. The mutant
eEF1A2 3′ UTRs was obtained by overlap extension
PCR. The fragments were cloned into a pmir-GLO re-
porter vector (Promega), downstream of the luciferase
gene, to generate the recombinant vectors pmir-GLO-
eEF1A2-wt and pmir-GLO-eEF1A2-mut. For the luciferase
reporter assay, PANC-1 and AsPC-1 were transiently co-
transfected with miRNA (miR-633 agomir or miR-633
scramble) and reporter vectors (wild-type reporter vectors or
mutant-type reporter vectors), using Lipofectamine™ 2000.
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assay kit (Promega) according to manufacturer’s instructions
at 48 h post-transfection.
Statistical analyses
All statistical analyses were performed using SPSS 17.0
software. The Student t test or one-way ANOVA was
conducted for normally distributed data. The Pearson χ2
test was used to determine the correlation between miR-
663 expression and clinicopathologic features of patients.
Patients’ survival was analyzed in the Kaplan-Meier method,
using the log-rank test for comparison. All data represent
mean ± SD. Statistical significance was set at p < 0.05.
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